Although the potential utility of FAP immunohistochemistry and plasma FAP as a biomarker in renal tumors for the differential diagnosis at an early stage have previously been reported (11), there have to date been no comparable studies with respect to pancreatic cancer. This evidence concerns the gene FAP and pancreatic neoplasm.